SecBot SecBot
8-K ·Filed May 1, 2026

MANE

Veradermics, Inc
NEUTRAL
Impact 5/10
Horizonweeks Processed5mo ago SEC0001628280-26-029376
Killer combo: Material agreement + unregistered equity (likely PIPE/convertible)
Actionable Insight • Neutral

Monitor stock for potential selling pressure as new shares enter the market, but the offering at market price indicates strong demand. The $414M cash infusion provides ample runway for development-stage operations.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
MANE ▲ +2.38% at T+60d
NEUTRAL call +2.38% · α vs SPY +0.52% · entry $105.26 → $107.76
Entry = T+0 close
May 1, 2026
via day close
T+1d
0.00%
call 0.00% · α -0.80%
$105.26
settled 6mo ago
T+5d
+2.73%
call +2.73% · α -0.21%
$108.13
settled 6mo ago
T+20d
-3.56%
call -3.56% · α -9.21%
$101.51
settled 5mo ago
T+60d
+2.38%
call +2.38% · α +0.52%
$107.76
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Veradermics closed an underwritten public offering of 3,843,790 shares at $100.00 per share, raising ~$384M, and a concurrent private placement of pre-funded warrants for 300,000 shares at $99.99999 each, raising $30M. Net proceeds will be used for general corporate purposes.

Key Financial Metrics

Offering Size
$414.4M
Dilution
11.2%

Key Facts

  • Public offering of 3,843,790 shares at $100.00 per share, plus 30-day over-allotment of 576,568 shares
  • Private placement of pre-funded warrants for 300,000 shares at $99.99999 per warrant, ~$30M gross
  • Combined gross proceeds ~$414M
  • Pre-funded warrants have exercise price of $0.00001, do not expire, subject to 9.99% beneficial ownership limitation
  • Private placement investors are entities affiliated with Suvretta Capital

Financial Impact

~$414M gross proceeds from combined offerings

dilutioncash_position

Risk Factors

  • Dilution of ~11% from new shares and potential exercise of pre-funded warrants
  • Lock-up restrictions on certain shares for 90 days may limit near-term selling

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-029376
Exhibit: exhibit41-closing8xk.htm0001628280-26-029376
Document: mane-20260501.htm0001628280-26-029376
Document: 0001628280-26-029376-index-headers.html0001628280-26-029376
Document: 0001628280-26-029376-index.html0001628280-26-029376
Document: 0001628280-26-029376.txt0001628280-26-029376
13 reports for MANE
Performance horizon
60% Hit rate @ T+5 3 of 5 directional calls Went positive at some point 5 of 6 best @ T+60▲ +9.74%Apr 27, 2026
Filters
Rows
Reports for MANE — sortable, filterable
TypeNow
Oct 19, 2026
7d ago
8-K
BULLISH ★ 7/10
$122.28awaiting T+5—$137.39 (+12.36%)
Oct 13, 2026
13d ago
SC 13G
NEUTRAL ★ 4/10
$116.26 $127.11▲ +9.33%▲ +10.48%$137.39 (+18.17%)
Aug 21, 2026
9w ago
Insider Cluster
BEARISH ★ 5/10
$98.46 $98.41▲ +0.05%▲ +0.52%$137.39 (−39.54%)
Aug 20, 2026
9w ago
3
NEUTRAL ★ 2/10
$102.82 $97.93▼ −4.76%▼ −5.23%$137.39 (+33.62%)
Aug 18, 2026
9w ago
Insider Cluster
NEUTRAL ★ 3/10
$111.23 $102.80▼ −7.58%▼ −7.19%$137.39 (+23.52%)
Aug 11, 2026
10w ago
8-K
NEUTRAL ★ 5/10
$110.75 $111.31▲ +0.51%▲ +0.91%$137.39 (+24.05%)
Aug 7, 2026
11w ago
S-1
BEARISH ★ 7/10
$110.75 $108.22▲ +2.28%▲ +2.24%$137.39 (−24.05%)
Aug 7, 2026
11w ago
Institutional Cluster
BULLISH ★ 6/10
$114.39 $112.71▼ −1.47%▼ −1.87%$137.39 (+20.11%)
Jul 15, 2026
14w ago
8-K
BULLISH ★ 6/10
$123.70 $109.85▼ −11.20%▼ −10.22%$137.39 (+11.07%)
May 12, 2026
23w ago
8-K
NEUTRAL ★ 5/10
$103.90 $100.38▼ −3.39%▼ −3.47%$137.39 (+32.23%)
Showing 10 of 13

US Market Status

Market Closed — Opens Tue (16h 40m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 1, 2026